BRAF and K-ras mutations in colorectal cancers
| Alteration | No of cases | BRAF | p Value† | K-ras | p Value† |
|---|---|---|---|---|---|
| HNPCC, hereditary non-polyposis colorectal cancer; MSI-H, high level microsatellite instability; CIMP, CpG island methylator phenotype; CRC, colorectal cancer. | |||||
| *CIMP status was determined using four markers (MINT 1, MINT 2, MINT 12 and MINT 31); CIMP-high, 3–4 markers methylated; CIMP-low, 1–2 markers methylated; CIMP negative, no marker methylated. | |||||
| †We used Pearson’s χ2 test or Fisher’s exact test (extended) where appropriate to compare all variables. | |||||
| Patients with HNPCC | 18 | 0 (0%) | 6 (33%) | ||
| Microsatellite status | — | — | |||
| MSI-H | 18 | 0 (0%) | 6 (33%) | ||
| Non-MSI-H | 0 | 0 (0%) | 0 (0%) | ||
| CIMP status* | — | 1 | |||
| CIMP-high | 0 | 0 (0%) | 0 (0%) | ||
| CIMP-low | 3 | 0 (0%) | 1 (33%) | ||
| CIMP-negative | 15 | 0 (0%) | 5 (33%) | ||
| Patients with sporadic CRC | 127 | 42 (33%) | 37 (29%) | ||
| Microsatellite status | <0.0001 | <0.0001 | |||
| MSI-H | 46 | 35 (76%) | 1 (2%) | ||
| Non-MSI-H | 81 | 7 (9%) | 36 (44%) | ||
| CIMP status* | <0.0001 | 0.05 | |||
| CIMP-high | 26 | 20 (77%) | 4 (15%) | ||
| CIMP-low | 44 | 8 (18%) | 19 (43%) | ||
| CIMP-negative | 34 | 0 (0%) | 10 (29%) | ||